Entrectinib drug profile

Entrectinib is a new type of targeted therapy drug, mainly used to treat specific types of cancer, including NTRK gene fusion-positive tumors and ROS1-positive non-small cell lung cancer. This drug works by interfering with key signaling pathways required for tumor cell growth, and has high selectivity and efficacy.

Enrectinib targets NTRK gene fusion-positive tumors. NTRKGene fusion is a rare but important molecular abnormality that can lead to abnormal proliferation and growth of tumor cells. Entrectinib can specifically inhibit the activity of NTRK protein, blocking the abnormal activation of this signaling pathway, thereby inhibiting the proliferation and spread of tumor cells. This is an important treatment advance for patients with NTRK gene fusion-positive tumors, providing a gene-specific treatment option.

Enrectinib is also effective in treatingROS1positive non-small cell lung cancer. ROS1Gene fusion is another important type of molecular mutation in non-small cell lung cancer, and patients often become resistant to traditional treatments. As a targeted therapy drug, entrectinib can effectively inhibit the activity of ROS1 protein, thereby inhibiting the growth and spread of tumors, providing a new treatment option for patients with ROS1-positive non-small cell lung cancer.

Overall, entrectinib, as a targeted therapy, has high selectivity and efficacy, and is an important therapeutic advancement for patients with NTRK gene fusion-positive tumors and ROS1-positive non-small cell lung cancer. However, like other drugs, entrectinib may also cause some side effects, including but not limited to nausea, fatigue, vomiting, dizziness, etc., so it should be used according to the guidance of a doctor and regularly monitored and evaluated.